irAE immune-related adverse events immune-mediated adverse events hepatitis pneumonitis rash diabetes

A series of articles will be published on the management of irAE. For members only. Register now and get full access. It’s free!

U.S. FDA Approved Immune-Checkpoint Inhibitors Updated 19-Jun-2018

Since 2011, when the United States Food and Drug Administration (U.S. FDA) approved ipilimumab (Yervoy®) for malignant melanoma, several immune-checkpoint inhibitors have been granted marketing authorisation. Do you know all the indications? MediPaper made an overview of all the U.S. FDA approved immune-checkpoint inhibitors and other U.S. FDA approved immunotherapies.

Herbert Loong on irAEs Immunotherapy (I-O) and New Onset Diabetes or immune-mediated diabetes

I-O in Special Populations: Diabetes and Concomitant Steroids

There is no excerpt because this is a protected post.

Nivolumab Renal Cell Cancer Symposium Highlight

Nivolumab for Renal Carcinoma: Getting the Most Out of PD-1 Immunotherapy

There is no excerpt because this is a protected post.